First report of the randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI monotherapy for chemorefractory metastatic colorectal cancer (mCRC): JCOG2014 (ROBiTS).

Authors :: Satake, Hironaga
Yamazaki, Kentaro
Suwa, Yusuke
Tsushima, Takahiro
Ishizuka, Yasunobu
Boku, Shogen
Takashima, Atsuo
Yamaguchi, Toshifumi
Asayama, Masako
Yokota, Mitsuru
Numata, Koji
Ohta, Takashi
Yasui, Hisateru
Kito, Yosuke
Takii, Yasumasa
Kitabayashi, Ryo
Sano, Yusuke
Fukuda, Haruhiko
Hamaguchi, Tetsuya
Kanemitsu, Yukihide
Source :: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p118-118, 235p
Publication Year :: 2024

Full Text Access

Tools